About This Journal:

  • Print This Page
  • Subscribe to an RSS Feed
My Liebert Connect

Sign up to stay informed--receive email notifications for this journal

Theranostics and Companion Diagnostics Forum

Editor-in-Chief: Stephen C. Pieper, MD

• Online ISSN: 2573-3362 • Continuous Publication


Launching in 2018!

Theranostics and Companion Diagnostics Forum is an innovative open access journal covering the clinical and scientific advances of merging targeted drug therapy and diagnostics to advance personalized medicine. The Journal provides a publication venue for basic, translational science, and clinical articles reporting scientific advances in theranostics research and the use of companion diagnostics in healthcare.

The Journal publishes basic science and translational research in the form of original research articles, comprehensive review articles, mini-reviews, rapid communications, brief reports, technology reports, hypothesis articles, perspectives, and letters to the editor. All articles published in Theranostics and Companion Diagnostics Forum are peer-reviewed and published online within 4 weeks of acceptance. Theranostics and Companion Diagnostics Forum publishes under the Creative Commons Attribution 4.0 (CC BY) license to ensure broad dissemination. The Journal is fully compliant with NIH-, HHMI-, Wellcome Trust, and most research funder policies.

Theranostisc and Companion Diagnostics Forum coverage includes:

  • In vitro diagnostics and prognostics
  • In vivo molecular imaging
  • Nanotheranostics, materials, and nanomedicine 
  • Molecular therapeutics
  • Image-guided therapy
  • Biosensor, nanobiosensor and bioelectronics
  • Targeted drug therapy for personalized medicine

Theranostics and Companion Diagnostics Forum is under the editorial leadership of Stephen C. Pieper, MD, Professor and Chair, Department of Pathology, Anatomy & Cell Biology, Thomas Jefferson University.

Audience: Oncologists, pharmacologists, nuclear medicine researchers, radiologists, cancer researchers, pathologists, and epidemiologists, drug discovery and developmental scientists, pharmaceutical and biotechnology researchers, and medical geneticists

Benefits of publishing in the Journal include:

  • High visibility, immediate and unrestricted online access to published articles
  • Rigorous and rapid peer review
  • Easy compliance with open access mandates
  • Authors retain copyright
  • Highly indexed – citation tracking and inclusion in bibliographic databases
  • Targeted email marketing

Publisher Contact:
Jordan L. Schilling
Director of Open Access Publishing
Mary Ann Liebert, Inc., publishers
Phone: 914-740-2100


The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.

Recommended Publications

You may be interested in the following publications:

    Genetic Testing and Molecular Biomarkers

    Genetic Testing and Molecular Biomarkers

    Covers all areas of molecular, biochemical, and clinical genetic testing; ethical, legal, social, and economic aspects of genetic testing; issues concerning effective genetic counseling; and molecular biomarkers.

    ASSAY and Drug Development Technologies

    ASSAY and Drug Development Technologies

    This authoritative, rapidly peer-reviewed journal features original articles, application-oriented technology reviews, and reports in methodology and technology application.

    Cancer Biotherapy and Radiopharmaceuticals

    Cancer Biotherapy and Radiopharmaceuticals

    The established journal with over 30 years of peer-reviewed papers on new and innovative investigations of methods to improve cancer therapy. The Journal focuses on advancements in radioimmunotherapy and radiopharmaceuticals.

    Clinical OMICs

    Clinical OMICs

    The go-to resource for clinicians interested in the transfer of OMICs technologies into the clinic.

    Genetic Engineering & Biotechnology News

    Genetic Engineering & Biotechnology News

    The mostly widely-read publication covering tools, techniques, and technologies in the biotechnology industry.

Browse All Publications »